VX-150

Vertex Pharmaceuticals Incorporated · Phase 2 active Small molecule

At a glance

Generic name	VX-150
Sponsor	Vertex Pharmaceuticals Incorporated
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Microneurography Study of NaV1.8 Inhibition in Healthy Adults (PHASE1)
A Microneurography (MNG) Study of VX-150 in Healthy Participants (PHASE1)
A Dose-ranging Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy (PHASE2)
A Study to Evaluate the Efficacy and Safety of VX-150 in Treating Subjects With Pain Caused by Small Fiber Neuropathy (PHASE2)
A Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy (PHASE2)
A Study of the Efficacy and Safety of VX-150 in Subjects With Osteoarthritis of the Knee (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

VX-150 CI brief — competitive landscape report
VX-150 updates RSS · CI watch RSS
Vertex Pharmaceuticals Incorporated portfolio CI